×
Be proactive in fracture prevention
https://www.mdedge.com/rheumatology/article/214488/osteoporosis/be-proactive-fracture-prevention?channel=53
Elizabeth Shane, MD

Dec 18th, 2019 - Several studies published over the last few years have shown declining rates of diagnosis and treatment of osteoporosis in older adults. In part, this may be due to declining ability to diagnose osteoporosis because declining reimbursement for dual x-ray absorptiometry has made it less available to patients and doctors.

Osteoporotic fracture risk is undermanaged in older adults
https://www.mdedge.com/internalmedicine/article/214483/osteoporosis/osteoporotic-fracture-risk-undermanaged-older-adults?channel=290
Heidi Splete

Dec 18th, 2019 - Treatment of osteoporosis in older adults at increased risk for fractures declined from 2010 to 2014, based on a study of nearly 900,000 individuals. Courtesy University of Alabama at Birmingham Dr.

Well-tolerated topical capsaicin formulation reduces knee OA pain
https://www.mdedge.com/internalmedicine/article/214467/osteoarthritis/well-tolerated-topical-capsaicin-formulation-reduces?channel=290
Jeff Craven

Dec 18th, 2019 - ATLANTA – Use of high-concentration topical capsaicin was associated with reduced pain, a longer duration of clinical response, and was well tolerated in patients with knee osteoarthritis, compared with lower concentrations of capsaicin and placebo, according to recent research presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Tim Warneke While the.

Hydroxychloroquine prevents congenital heart block recurrence in anti-Ro pregnancies
https://www.mdedge.com/internalmedicine/article/214451/lupus-connective-tissue-diseases/hydroxychloroquine-prevents?channel=290
M. Alexander Otto

Dec 17th, 2019 - ATLANTA – Hydroxychloroquine (Plaquenil) 400 mg/day starting by pregnancy week 10 reduces recurrence of congenital heart block in infants born to women with anti-Ro antibodies, according to an open-label, prospective study presented at the annual meeting of the American College of Rheumatology. M.

ACR and EULAR release first classification criteria for IgG4-related disease
https://www.mdedge.com/internalmedicine/article/214448/lupus-connective-tissue-diseases/acr-and-eular-release-first?channel=290
Jeff Craven

Dec 17th, 2019 - The American College of Rheumatology and the European League Against Rheumatism have released the first classification criteria for IgG4-related disease. Although it was first recognized as a distinct disease in 2003, investigators have since learned that IgG4-related disease (IgG4-RD) is not particularly rare.

VEDOSS study describes predictors of progression to systemic sclerosis
https://www.mdedge.com/dermatology/article/214179/lupus-connective-tissue-diseases/vedoss-study-describes-predictors?channel=39313
Jeff Craven

Dec 12th, 2019 - ATLANTA – Patients with Raynaud’s phenomenon and puffy fingers, disease-specific antibodies, and/or nailfold video capillaroscopy abnormalities were more likely to progress to systemic sclerosis within 5 years than were patients without those features, according to recent results from the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study presented at the annual meeting of the American C.

ADA2 is a potent new biomarker for macrophage activation syndrome
https://www.mdedge.com/fedprac/article/214103/pediatrics/ada2-potent-new-biomarker-macrophage-activation-syndrome?channel=285
M. Alexander Otto

Dec 11th, 2019 - ATLANTA – Adenosine deaminase 2 above the upper limit of normal is 86% sensitive and 94% specific for distinguishing macrophage activation syndrome from active systemic juvenile idiopathic arthritis, making it perhaps the most potent blood marker yet identified to differentiate the two, according to a report presented at the annual meeting of the American College of Rheumatology. Dr.

Tofacitinib improves disease activity in patients with polyarticular-course JIA
https://www.mdedge.com/fedprac/article/214064/pediatrics/tofacitinib-improves-disease-activity-patients-polyarticular?channel=285
Jeff Craven

Dec 11th, 2019 - ATLANTA – Treatment of polyarticular-course juvenile idiopathic arthritis with tofacitinib led to significantly fewer disease flares and greater improvement in disease activity than with placebo in a phase 3, multinational, randomized, double-blind, controlled withdrawal study presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Repeat LTBI testing best in patients taking biologics with new risk factors
https://www.mdedge.com/fedprac/article/213923/rheumatoid-arthritis/repeat-ltbi-testing-best-patients-taking-biologics-new?channel=234
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients taking biologics who received latent tuberculosis testing on an annual basis were unlikely to convert from a negative QuantiFERON test to a positive result, which suggests that the test may be unnecessary for patients without new tuberculosis risk factors, according to research presented at the annual meeting of the American College of Rheumatology. In addition, nearly all of.

Perioperative antirheumatic drug use does not impact postsurgery infection rate in RA patients
https://www.mdedge.com/jcomjournal/article/213883/rheumatoid-arthritis/perioperative-antirheumatic-drug-use-does-not-impact?channel=302
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients with rheumatoid arthritis were more at risk of postoperative infection because of a high Charlson Comorbidity Index or longer surgery time than because of perioperative use of antirheumatic medications, according to a presentation at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Updated gout guidelines: Don’t let kidney function dictate allopurinol dosing
https://www.mdedge.com/clinicianreviews/article/213863/gout/updated-gout-guidelines-dont-let-kidney-function-dictate?channel=53
M. Alexander Otto

Dec 9th, 2019 - ATLANTA – Soon-to-be-published gout guidelines from the American College of Rheumatology will recommend dosing allopurinol above 300 mg/day to get serum urate below 6 mg/dL, even in people with renal impairment. M.

Evidence grows for early axSpA treatment, uveitis flare prevention
https://www.mdedge.com/rheumatology/article/213740/ankylosing-spondylitis/evidence-grows-early-axspa-treatment-uveitis?channel=299
Denis Poddubnyy, MD

Dec 6th, 2019 - The findings from the C-axSpAnd study that Jonathan Kay, MD, and colleagues reported at the annual meeting of the American College of Rheumatology are not surprising. Earlier studies in patients with ankylosing spondylitis showed that short symptom duration is one of the best predictors of good treatment response to TNFi therapy.

Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
https://www.mdedge.com/internalmedicine/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs?channel=53
Sharon Worcester

Dec 3rd, 2019 - ATLANTA – Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, significantly improved the signs and symptoms of active ankylosing spondylitis, compared with placebo, in the randomized, placebo-controlled, phase 2/3 SELECT-AXIS 1 study. Dr.

Tanezumab posts higher safety event rate than NSAIDs over 1 year in hip, knee OA
https://www.mdedge.com/rheumatology/article/213000/osteoarthritis/tanezumab-posts-higher-safety-event-rate-nsaids-over-1?channel=53
Jeff Craven

Nov 25th, 2019 - ATLANTA – Patients with moderate to severe osteoarthritis of the hip and knee who took the investigational anti-nerve growth factor monoclonal antibody tanezumab experienced a significantly higher rate of joint safety events than that of patients who received NSAIDs as part of a recent randomized, double-blind, active-controlled, phase 3 study. Jeff Craven/MDedge News Dr.

Large population-based study underscores link between gout, CVD event risk
https://www.mdedge.com/cardiology/article/212979/gout/large-population-based-study-underscores-link-between-gout-cvd-event?channel=39313
Sharon Worcester

Nov 23rd, 2019 - ATLANTA – Gout is associated with an increased risk of both fatal and nonfatal cardiovascular disease events, according to a large population-based health data linkage study in New Zealand. Sharon Worcester/MDedge News Dr.

SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
https://www.mdedge.com/rheumatology/psoriatic-arthritis-resource-center/article/212887/psoriatic-arthritis/spirit-h2h?channel=281
Sharon Worcester

Nov 21st, 2019 - ATLANTA – Ixekizumab (Taltz) provided significantly greater improvement in joint and skin symptoms, compared with adalimumab (Humira), in biologic-naive patients with active psoriatic arthritis (PsA), according to final 52-week safety and efficacy results from the randomized SPIRIT-H2H study. Dr.

COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placebo
https://www.mdedge.com/rheumatology/article/212841/ankylosing-spondylitis/coast-x-top-line-results-ixekizumab-improves?channel=53
Sharon Worcester

Nov 21st, 2019 - ATLANTA – Adding ixekizumab (Taltz) to conventional background medications significantly improved the signs and symptoms of nonradiographic axial spondyloarthritis (axSpA) in the randomized, double-blind, placebo-controlled phase 3 COAST-X trial. Sharon Worcester/MDedge News Dr.

Fewer people are dying from systemic sclerosis at younger ages
https://www.mdedge.com/internalmedicine/article/212836/lupus-connective-tissue-diseases/fewer-people-are-dying-systemic?channel=290
Jeff Craven

Nov 21st, 2019 - ATLANTA – Patients with systemic sclerosis aged 44 years and younger in the United States now have mortality comparable to that of the general population in that age group, according to recent results presented at the annual meeting of the American College of Rheumatology. Dr.

Rituximab tops azathioprine for relapsing ANCA-associated vasculitis remission maintenance
https://www.mdedge.com/internalmedicine/article/212794/lupus-connective-tissue-diseases/rituximab-tops-azathioprine?channel=290
M. Alexander Otto

Nov 21st, 2019 - ATLANTA – Rituximab (Rituxan) is superior to azathioprine (Imuran) for preventing ANCA-associated vasculitis relapses in patients with histories of previous relapses, according to a randomized trial of 170 patients presented at the annual meeting of the American College of Rheumatology. Dr.

Biologic DMARDs appear as effective in elderly-onset RA as in young-onset RA
https://www.mdedge.com/rheumatology/article/212492/rheumatoid-arthritis/biologic-dmards-appear-effective-elderly-onset-ra?channel=53
Sharon Worcester

Nov 18th, 2019 - ATLANTA – Elderly-onset and young-onset rheumatoid arthritis patients initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) respond similarly with respect to clinical improvement at 48 weeks and adverse events, data from a large registry in Japan suggest. Sharon Worcester/MDedge News Dr.